

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-267US	Serial No.: 10/525,439
	Applicants: MEHTA <i>et al.</i>	
	Filed: 2/23/2005	Group: 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JN	A1	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
JN	A2	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
JN	A3	5,397,800	3/14/1995	Alker <i>et al.</i>	514	413	
JN	A4	5,735,690	4/7/1998	Malentacca	433	102	
JN	A5	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
JN	A6	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
JN	A7	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
JN	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54	
JN	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08	
JN	B3	EP 0 413 455	2/20/1991	EPO	C07D	401/04	
JN	B4	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
JN	B5	GB 940,540	10/30/1963	UK	C07C		
JN	B6	JP 135989/1994	5/17/1995	Japan	C07D	333/16	
JN	B7	JP 92921/1994	4/5/1994	Japan	C07C	237/20	
JN	B8	WO 91/09013	6/27/1991	PCT	C07D	207/08	
JN	B9	WO 93/16018	8/19/1993	PCT	C05F	17/02	
JN	B10	WO 93/16048	8/19/1993	PCT	C07D	211/26	
JN	B11	WO 95/15312	6/8/1995	PCT	C07D	209/52	
JN	B12	WO 95/15327	6/8/1995	PCT	C07D	487/04	
JN	B13	WO 96/33973	10/31/1996	PCT	C07D	211/46	
JN	B14	WO 97/36906	10/9/1997	PCT	C07D	487/08	
EXAMINER /Jason Nolan/				DATE CONSIDERED 12/01/2006			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-267US		Serial No.: 10/525,439	
	Applicants: MEHTA et al.			
	Filed: 2/23/2005		Group: 1626	

JN	B15	WO 97/45414	12/4/1997	PCT	C07D	211/58	
JN	B16	WO 98/05641	2/12/1998	PCT	C07D	211/46	
JN	B17	WO 98/29402	7/9/1998	PCT	C07D	311/20	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JN	C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , <u>323</u> (2):411-416 (1986)					
JN	C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , <u>237</u> :527-531 (1987)					
JN	C3	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , <u>3</u> :426-432 (1999)					
JN	C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)					
JN	C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (23):4333-4353 (2000)					
JN	C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , <u>6</u> :142-193 (2001)					
JN	C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (5):215-219 (2001)					
JN	C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , <u>41</u> :691-721 (2001)					
JN	C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , <u>2</u> (3):268-282					
JN	C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , <u>55</u> (Suppl. 5A):33-46 (2000)					
JN	C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)					
JN	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M ₃ Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , <u>45</u> (4):984-987 (2002)					
JN	C13	Mase et al., "Synthesis of a Muscarinic Receptor Antagonist via a Diastereoselective Michael Reaction, Selective Deoxyfluorination and Aromatic Metal-Halogen Exchange Reaction", <i>Journal of Organic Chemistry</i> , <u>66</u> (20):6775-6786 (2001)					
JN	C14	Mitsuya et al., "Discovery of a Muscarinic M ₃ Receptor Antagonist with High Selectivity for M ₃ Over M ₂ Receptors Among 2-[(1S,3S)-3-Sulfonylaminocyclopentyl]phenylacetamide Derivatives" <i>Bioorganic & Medicinal Chemistry</i> , <u>8</u> :825-832 (2000)					

EXAMINER	/Jason Nolan/	DATE CONSIDERED	12/01/2006
----------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-267US	Serial No.: 10/525,439
	Applicants: MEHTA <i>et al.</i>	
	Filed: 2/23/2005	Group: 1626

JN	C15	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , <u>65</u> :6283-6287 (2000)
JN	C16	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
JN	C17	Cheng and Prusoff, "Relationship between the inhibition constant (<i>K</i> ₁) and the concentration of inhibitor which causes 50 per cent inhibition (<i>I</i> ₅₀) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , <u>22</u> :3099-3108 (1973)
JN	C18	Jeppesen et al., "1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0 ^{2,6}]heptanes as New Potent Muscarinic M ₁ Agonists: Structure-Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives", <i>Journal of Medicinal Chemistry</i> , <u>42</u> (11):1999-2006 (1999)

EXAMINER	/Jason Nolan/	DATE CONSIDERED	12/01/2006
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>			